Literature DB >> 19287966

CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers.

Wataru Habano1, Toshie Gamo, Tamotsu Sugai, Koki Otsuka, Go Wakabayashi, Shogo Ozawa.   

Abstract

Cytochrome P450 (CYP) 1A1 (CYP1A1) and CYP1B1, dioxin-inducible CYP1s, are associated with carcinogenesis in extrahepatic tissues. CYP1B1 is featured in carcinogenesis of hormone-responsive tissues, where the CYP1B1 level is considerably high. Although aberrant expression of these enzymes is also observed in cancers that are not related to hormone response, their roles in carcinogenesis are not yet fully understood. We examined DNA methylation status of the CpG islands within the 5'-flanking region of the CYP1B1 and CYP1A1 genes in 7 colorectal cancer cell lines and 40 primary colorectal cancers. By bisulfite-modified direct sequencing, CYP1B1 gene methylation was detected in 2 cell lines (SW48 and Caco-2) and 2 (5%) cancers, but not in corresponding normal tissues. Treatment of the cells with 5-aza-2'-deoxycytidine revealed a clear increase in the CYP1B1 mRNA levels in SW48 and Caco-2 cells, while the amount of methylated alleles decreased. Only HT29 cells showed a clear increase in CYP1A1 mRNA, although there were no apparent differences in methylation status among these cell lines. None of these cell lines showed significant change in mRNA levels of aryl hydrocarbon receptor (AhR) and AhR nuclear translocator (ARNT), which are known to directly activate CYP1 transcription. This observation suggested that expression of CYP1B1, but not CYP1A1, was downregulated by promoter methylation rather than decreased expression of AhR/ARNT. In conclusion, CpG methylation of the CYP1B1 promoter region epigenetically regulates CYP1B1 expression during development of some colorectal cancers. Moreover, cancers with aberrant CYP1B1 expression might show altered response to procarcinogen metabolism and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19287966     DOI: 10.3892/ijo_00000235

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

Review 1.  Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s.

Authors:  Viola Tamási; Katalin Monostory; Russell A Prough; András Falus
Journal:  Cell Mol Life Sci       Date:  2010-12-24       Impact factor: 9.261

2.  Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport.

Authors:  Magnus Ingelman-Sundberg; Xiao-Bo Zhong; Oliver Hankinson; Sudheer Beedanagari; Ai-Ming Yu; Lai Peng; Yoichi Osawa
Journal:  Drug Metab Dispos       Date:  2013-08-05       Impact factor: 3.922

Review 3.  Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.

Authors:  Cristina Rodriguez-Antona; Alvin Gomez; Maria Karlgren; Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Hum Genet       Date:  2009-10-08       Impact factor: 4.132

4.  Modulation of aryl hydrocarbon receptor (AHR)-dependent signaling by peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in keratinocytes.

Authors:  Michael G Borland; Prasad Krishnan; Christina Lee; Prajakta P Albrecht; Weiwei Shan; Moses T Bility; Craig B Marcus; Jyh M Lin; Shantu Amin; Frank J Gonzalez; Gary H Perdew; Jeffrey M Peters
Journal:  Carcinogenesis       Date:  2014-03-17       Impact factor: 4.944

5.  APC2 and CYP1B1 methylation changes in the bone marrow of acute myeloid leukemia patients during chemotherapy.

Authors:  Yongming Xia; Qingxiao Hong; Xiaoying Chen; Huadan Ye; Lili Fang; Annan Zhou; Yuting Gao; Danjie Jiang; Shiwei Duan
Journal:  Exp Ther Med       Date:  2016-09-20       Impact factor: 2.447

6.  Differential suppression of the aryl hydrocarbon receptor nuclear translocator-dependent function by an aryl hydrocarbon receptor PAS-A-derived inhibitory molecule.

Authors:  Jinghang Xie; Xin Huang; Miki S Park; Hang M Pham; William K Chan
Journal:  Biochem Pharmacol       Date:  2014-01-28       Impact factor: 5.858

7.  Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes.

Authors:  Sudheer R Beedanagari; Robert T Taylor; Peter Bui; Feng Wang; Derek W Nickerson; Oliver Hankinson
Journal:  Mol Pharmacol       Date:  2010-07-14       Impact factor: 4.436

8.  Effects on specific promoter DNA methylation in zebrafish embryos and larvae following benzo[a]pyrene exposure.

Authors:  J Corrales; X Fang; C Thornton; W Mei; W B Barbazuk; M Duke; B E Scheffler; K L Willett
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2014-02-24       Impact factor: 3.228

Review 9.  Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response.

Authors:  Ramón Cacabelos; Clara Torrellas
Journal:  Int J Mol Sci       Date:  2015-12-21       Impact factor: 5.923

10.  Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells.

Authors:  Wataru Habano; Toshie Gamo; Jun Terashima; Tamotsu Sugai; Koki Otsuka; Go Wakabayashi; Shogo Ozawa
Journal:  BMC Cancer       Date:  2011-02-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.